Home > Cardiology > AHA 2020 > Miscellaneous > Rilonacept reduces risk of pericarditis recurrence

Rilonacept reduces risk of pericarditis recurrence

Presented By
Dr Alan Klein, Cleveland Clinic, USA
Conference
AHA 2020
Trial
Phase 3, RHAPSODY

In patients with symptomatic recurrent pericarditis failing standard of care, addition of the interleukin (IL) 1α/1β inhibitor rilonacept resolved pericarditis episodes in the RHAPSODY trial. Rilonacept monotherapy reduced the risk of pericarditis recurrence by 96%. The treatment also had corticosteroid-sparing effects and improved quality of life [1,2].

Dr Alan Klein (Cleveland Clinic, USA) presented the main results of the RHAPSODY trial (NCT03737110). As Dr Klein explained, recurrent pericarditis is a debilitating disease with no (FDA) approved therapies; typically a combination of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and steroids is given. In the long run, steroids are associated with significant morbidity. IL-1 has been implicated as a key mediator in recurrent peric...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on